Abstract: A support plate mounted on the inner side wall of an inner drum has a through hole corresponding to drain openings formed in the wall of the drum, and a gap between the support plate and the side wall of the inner drum forms a space for valve plugs of sealing valves to move up and down; a mounting sleeve installed on the upper side of the support plate has an inner through hole coaxially arranged with the through hole in the support plate, so that the valve plugs of the sealing valves are coaxially installed in the inner through hole and can move up and down. A drain opening formed in the side wall of the inner drum is provided with a sealing valve installed on the inner drum via the sealing valve structure.

Abstract: A straight guide rail extending in an X direction is provided in a sewing platform portion for installing in a fixed state a pallet holding an object to be sewn, and first and second sewing machines are provided at left and right sides of the straight guide rail as viewed in the X direction. The first and second sewing machines are both provided with a movement support platform which allow the straight guide rail to reciprocate in the X direction, and the movement support platform is provided with a sewing machine body which is capable of reciprocating in a Y direction. The first and second sewing machines are program controlled in such a manner that any one thereof is capable of moving from one side of the straight guide rail toward the other side beyond a middle section thereof during the sewing operation of the first and second sewing machines.

Abstract: A stable crystal of a salt of N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide may have desirable properties for a pharmaceutical drug substance, and more specifically N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide dihydrochloride anhydride. A crystal of the anhydride may have characteristic peaks at 2? angles of 6.8±0.1°, 10.0±0.1°, 12.7±0.1°, 14.6±0.1°, 14.8±0.1°, 16.2±0.1°, 17.4±0.1°, 17.8±0.1°, 19.5±0.1°, 20.0±0.1°, 21.6±0.1°, 24.7±0.1°, 25.5±0.1°, 25.8±0.1°, 29.8±0.1°, 39.5±0.1°, and/or 44.9±0.1° in powder X-ray diffraction spectrum.

Abstract: An RNA interference (RNAi) strategy is provided based on use of artificial microRNA (amiR) to reduce NKCC1 expression. In particular, a method is provided that achieves neuron-specific expression of specific amiR against NKCC1 by using a human Synapsin promoter to drive transgene expression.

Abstract: Composition based on fatty alcohols and on alkyl polyrhamnosides; process for the preparation thereof; cosmetic or pharmaceutical composition comprising same; and use thereof as an emulsifier.

Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.

Abstract: A water treatment system includes an actinic radiation reactor and at least one ultraviolet (UV) lamp disposed within a quartz tube within the actinic radiation reactor. The at least one UV lamp includes a lamp tube including a gas that emits ultraviolet light responsive to electrical excitation, a first pinch extending from a first end of the lamp tube and a second pinch extending from a second end of the lamp tube, and a first end cap coupled to the first pinch and a second end cap coupled to the second pinch. The first end cap and second end cap are dimensioned to center the lamp tube coaxially within the quartz tube.

Abstract: The method for manufacturing a three-dimensional object or for modifying the surface state of a preformed object by local polymerisation of monomers or oligomers, the polymerisation being initiated by mono-photon or multi-photon absorption in an area to be polymerised, includes: —introducing into a vessel with light-transparent walls a reaction medium comprising polymerisable monomers or oligomers, a polymerisation inhibitor, an indicator of the amount of the inhibitor and a photochemical polymerisation initiator; —initiating the polymerisation of the monomers or oligomers; —indicating the amount of inhibitor present in the reaction medium; —controlling the amount of light emitted by the irradiation system relative to the amount of inhibitor indicated by the indicator; and —switching to a following zone to be polymerised by moving the object and/or the focused light beam.

Abstract: Systems and methods for tracking locations of movable assets within a space are disclosed. The systems include at least one tag configured for attachment to at least one movable asset and a plurality of anchors configured for measuring location data of the tag within the space. The tag and the anchors each include a transceiver module operable to measure location using, for example, ultrawide band or the global positioning system (GPS). The systems further include a listener in wireless communication with a communications portal or a mobile application on a mobile device, the listener is configured to receive location data from the tag and anchors and to transmit the location data to the communications portal or the mobile application. The systems also allow a user to create barriers for each of the tags within the space and alert the user when a tag moves beyond a barrier.

Abstract: Disclosed in the present invention is use of lysozyme in the preparation of a drug for preventing or treating a uric acid-related disease, a drug for reducing uric acid, and a drug for promoting uric acid excretion. Also disclosed in the present invention are a pharmaceutical composition for preventing or treating a uric acid-related disease, a pharmaceutical composition for reducing uric acid, and a pharmaceutical composition for promoting uric acid excretion, and a method for preventing or treating a uric acid-related disease, reducing uric acid and promoting uric acid excretion.

Abstract: A quantum processor performs input and output which may be performed synchronously. The quantum processor executes a problem to generate a classical output state, which is read out at least partially by an I/O system. The I/O system also transmits a classical input state to by the I/O system, which may include the same qubit-proximate devices used for read-out. The classical input state is written to the qubits, and the quantum processor executes based on the classical input state (e.g., by performing reverse annealing to transform the classical input state to quantum state).

Abstract: Systems, devices, and methods are provided for transseptal access of septa within a patient. The device can be advanced to a septum, e.g., towards a fossa ovalis. Instead of applying positive pressure to “tent” the septum, a negative pressure is applied to a lumen within a sheath, e.g., within an elongated member slidable within the sheath, via a negative pressure source such as a syringe on the proximal end of the sheath. This results in the septum pulling inward. The sheath employs a stationary needle-like central core component contained within the lumen of the sheath that punctures the septum when the same is pulled passed it by the negative pressure. The stationary needle-like central core component may be hollow and may form a portion of the elongated member or may be coupled to a distal end thereof.

Abstract: Salts of the compound represented by formula (I) or crystals thereof have a potential use as drug substances for pharmaceuticals.

Abstract: Systems, devices, and methods are provided for transseptal access of septa within a patient. The device can be advanced to a septum, e.g., towards a fossa ovalis. Instead of applying positive pressure to “tent” the septum, a negative pressure is applied to a lumen within a sheath, e.g., within an elongated member slidable within the sheath, via a negative pressure source such as a syringe on the proximal end of the sheath. This results in the septum pulling inward. The sheath employs a stationary needle-like central core component contained within the lumen of the sheath that punctures the septum when the same is pulled passed it by the negative pressure. The stationary needle-like central core component may be hollow and may form a portion of the elongated member or may be coupled to a distal end thereof.

Abstract: Systems, devices, articles, methods, and techniques for advancing quantum computing by removing unwanted interactions in one or more quantum processor. One approach includes creating an updated plurality of programmable parameters based at least in part on a received value for the characteristic magnetic susceptibility of the qubit in the at least one quantum processor, and returning the updated plurality of programmable parameters. Examples programmable parameters include local biases, and coupling values characterizing the problem Hamilton.

Abstract: A personal flotation system provides a horseshoe shaped float that is buoyant and can be used in a number or positions to float a person on the water and retain a beverage. The horseshoe shaped flotation device has a left and right armrest that extend out from an arced shaped closed end and dual cup holder, on the extended end of the armrest, has an cup cylinder to retain a beverage in the vertical orientation and an end cup holder to retain a beverage in an orthogonal orientation to the cup cylinder. The flotation device may have an extending strap that couples the left and right armrests together to secure the horseshoe shaped float around a person's torso.

Abstract: A superconducting circuit may include a transmission line having at least one transmission line inductance, a superconducting resonator, and a coupling capacitance that communicatively couples the superconducting resonator to the transmission line. The transmission line inductance may have a value selected to at least partially compensate for a variation in a characteristic impedance of the transmission line, the variation caused at least in part by the coupling capacitance. The coupling capacitance may be distributed along the length of the transmission line. A superconducting circuit may include a transmission line having at least one transmission line capacitance, a superconducting resonator, and a coupling inductance that communicatively couples the superconducting resonator to the transmission line. The transmission line capacitance may be selected to at least partially compensate for a variation in coupling strength between the superconducting resonator and the transmission line.

Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.

Abstract: The present invention relates to an anti-perspirant (AP) composition that comprises conventional metal-based AP actives, natural oil and select phenolic compounds that ensures that when such compositions are used on a body part e.g. the axilla there is minimal or no yellow coloured staining of the fabric which is worn by an individual through several use-wash-rinse-dry cycles.

Abstract: Disclosed are a pharmaceutical composition containing lysozyme and the use thereof in the preventing psoriasis, treating of psoriasis, and/or preventing of psoriasis recurrence. The pharmaceutical composition can significantly prolong the time before disease recurrence and significantly reduce the recurrence rate of diseases compared with the use of traditional oral drugs, immunosuppressive agents, biological agents, etc.